Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Shionogi & Co ( (JP:4507) ) is now available.
Shionogi & Co. reported a slight decline in revenue for the third quarter of FY 2024, with a 1% decrease compared to the previous year. Despite challenges in prescription drug sales, the company saw a substantial increase in royalty income, particularly from its HIV franchise, which contributed significantly to its overall profitability.
More about Shionogi & Co
Shionogi & Co., Ltd. operates in the pharmaceutical industry, focusing on the development and distribution of prescription drugs, particularly in the infectious disease sector. The company also engages in overseas subsidiaries and exports, alongside earning significant revenue from royalty income, primarily from its HIV franchise.
YTD Price Performance: 20.32%
Average Trading Volume: 531
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $13.36B
See more data about 4507 stock on TipRanks’ Stock Analysis page.
